Cyclo Therapeutics, Inc.
DelistedCIK 922247fmd_02E4PBV4256N3WQANSFS93BBQ0Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2010 to Sep 30, 2024, 58 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Gross profit | – | – | – | 1 | 1 | – | – | – | 1 | 1 |
| Research and development | 0 | 1 | 2 | 2 | 3 | 5 | 6 | 9 | 9 | 14 |
| Total operating expenses | 2 | 3 | 6 | – | – | – | – | – | – | – |
| Operating income | (1) | (2) | (4) | (4) | (4) | (8) | (9) | (14) | (16) | (20) |
| Interest expense | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (0) | (0) | 0 | 0 | – | 0 | 0 | 0 | (0) |
| Income before taxes | (1) | (2) | (4) | (4) | (4) | (8) | (9) | (14) | (15) | (20) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (3) | (4) | (4) | (4) | (8) | (9) | (14) | (15) | (20) |
| Net income | (1) | (3) | (4) | (4) | (4) | (8) | (9) | (14) | (15) | (20) |